X

ASH 2020 Highlights – DLBCL

ASH 2020 Highlights – DLBCL

Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

Patients with relapsed/refractory DLBCL given AUTO3 in combination with pembrolizumab experienced durable complete remissions, according to data presented by Aravind Ramakrishnan, MD.

Oncology Learning Network
12/18/2020
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma

This study reports on the first three consecutive patients with autologous CAR19-refractory LBCL treated with a single infusion of autologous 1×106 CAR+ T-cells/kg targeting...

Blood
12/18/2020
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

The prognosis for patients with LBCL, such as DLBCL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements/double-hit lymphoma, and primary mediastinal B-cell....

Blood Advances
12/11/2020

ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL

Many patients with diffuse large B-cell lymphoma may be cured by autologous stem cell transplant, but as many as half eventually relapse.

The ASCO Post
12/14/2020
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma

The phase II ZUMA-12 trial found axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma.

The ASCO Post
12/11/2020
Durable Responses Seen With Odronextamab in Refractory B-Cell NHLs

Odronextamab, demonstrated promising antitumor activity and an acceptable safety profile — including with cytokine release syndrome (CRS)–mitigating strategies — among patients with B-cell NHLs.

Cancer Therapy Advisor
12/07/2020
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy

This study showed CAR T-cell therapy was safe and effective in a DLBCL patient with coexisting autoimmune neuropathy.

Blood Advances
12/07/2020
Mosunetuzumab Safe, Effective for Elderly Patients With DLBCL

Single-agent mosunetuzumab demonstrated efficacy, remarkable safety, as a chemotherapy-free option for previously untreated elderly/unfit patients with DLBCL.

Oncology Learning Network
12/07/2020
Frailty Tied to Increased 1-Year Mortality in Patients with Newly Diagnosed DLBCL

According to data presented at the 2020 ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.

Oncology Learning Network
12/06/2020
Polatuzumab Vedotin Plus Venetoclax, Rituximab Shows Promise in R/R DLBCL

Polatuzumab vedotin plus venetoclax with rituximab (Pola-Ven-R) shows promise in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Oncology Learning Network
12/06/2020
ASH 2020: Early Research Shows CD58 May Be a Biomarker for Response to Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma

In a study presented at the 2020 ASH Annual Meeting & Exposition investigators reported CD58 status may be an important biomarker of durable response to CAR T-cell therapy in these patients

The ASCO Post
12/06/2020
Identifying potential germline variants from sequencing hematopoietic malignancies

Next-generation sequencing of bone marrow and peripheral blood increasingly guides clinical care in hematological malignancies.

Blood
11/26/2020
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Aberrant B-cell receptor (BCR)/NF-kB signaling is a hallmark feature of B-cell non-Hodgkin lymphomas, especially in diffuse large B-cell lymphoma.

Blood
11/24/2020
Is the CNS-PINK the new CNS risk model in ENKTL?

Apart from these specific subtypes, additional risk factors associated with CNS relapse have been most extensively explored in diffuse large B-cell lymphoma.

Blood
11/26/2020
CAR T-cell Therapy Hopes to Move to Second Line in Diffuse Large B-cell Lymphoma

This is an international, randomized, open-label, phase III clinical trial evaluating the efficacy of the autologous CD19-directed CAR-T therapy axicabtagene ciloleucel, versus second-line salvage.

10/12/2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Advanced marginal zone lymphoma is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of...

Blood Advances
11/23/2020
Next-generation cell therapies: the emerging role of CAR-NK cells

T cells engineered with chimeric antigen receptors have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell...

Blood Advances
11/24/2020
Does High-Dose Methotrexate Protect the CNS in High-Risk DLBCL?

A retrospective study found that treatment with high-dose methotrexate did not lower the risk of CNS relapse in patients with high-risk DLBCL bringing into question whether current...

12/07/2020
Addition of Tafasitamab to R-CHOP Is Safe for DLBCL

This study showed that R-CHOP in combination with tafasitamab with or without lenalidomide is a safe treatment option for patients with treatment-naïve DLBCL.

12/06/2020
Biomarker Identifies Lymphoma Patients Who Don’t Respond to Ibrutinib

The discovery of a new biomarker can help guide physicians toward the right treatment for patients with ABC-DLBCL who harbor these newly exposed mutations in the BCL10 gene.

12/07/2020
Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA

Obinutuzumab does not provide any significant additional tumor control in newly diagnosed transplant-eligible DLBCL compared to rituximab.

Blood
11/19/2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

In R/R HL, immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment.

Blood
11/19/2020
A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Sauter et al recently evaluated the prognostic significance of pretransplant DS in patients with R/R diffuse large B-cell lymphoma. Their study demonstrated that patients undergoing salvage ASCT...

Blood Advances
11/20/2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

CAR T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. This study identified factors that may predict failure...

Blood Advances
11/12/2020
Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab is an Fc-enhanced, humanized, monoclonal antibody that targets CD19, which is broadly expressed across B-cell malignancies, including DLBCL.

Blood
11/05/2020
NUSAP1 Promotes Cell Proliferation Via the DNA Damage Response Pathway in Diffuse Large B-Cell Lymphoma

NUSAP1 has been shown to be highly expressed in a variety of tumors, involved in tumor occurrence, invasion, migration, and drug resistance.

Blood
11/05/2020
The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

This study recently reported a new tool to help the early identification of ultra-high risk DLBCL patients.

Blood
11/05/2020
Socioeconomic Disparities in Diagnostic Testing Among Patients with Diffuse Large B-Cell Lymphoma in the US

Despite advances in treatment and increasing knowledge of clinical importance of DLBCL subtype classification, socioeconomic disparities persist in the treatment of DLBCL in the US...

Blood
11/05/2020
Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma

TCRLBCL is an aggressive variant of DLBCL characterized by rare malignant B cells within a robust but ineffective immune cell infiltrate. 

Blood
09/01/2020

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39